Jun 4, 2008 - Antares Pharma, Inc. (AMEX:AIS) a specialty pharmaceutical company, today reported that the United States Patent & Trademark Office (USPTO) has issued a Notice of Allowance for U. S. patent application 11/120,306 entitled "Permeation Enhancing Compositions For Anticholinergic Agents" related to Antares' Anturol(TM) product for the treatment of overactive bladder. The Notice of Allowance is the USPTO's official communication that the Company's application has successfully completed examination and that a patent will be issued.
Jack E. Stover, President and Chief Executive Officer, commented, "We are pleased to receive this notice of allowance which provides additional protection for our proprietary technology and products and most specifically for Anturol."
The details can be read here
No comments:
Post a Comment